NCT06647888View on ClinicalTrials.gov

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

RecruitingOBSERVATIONAL
Enrollment

12,000

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Envlo Tablet

Envlo Tab. 0.3mg

DRUG

Envlomet SR Tablet

Envlomet SR Tablet 0.3/ Metformin1,000mg

Trial Locations (1)

12254

RECRUITING

Happy Yonsei Family Medicine Clinic, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY